CASTLE BIOSCIENCES, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CASTLE BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $95.00K, a 400.00% increase year-over-year.
- CASTLE BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $322.00K, a 1688.89% increase year-over-year.
- CASTLE BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $77.00K, a 95.10% decline year-over-year.
- CASTLE BIOSCIENCES, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $19.00K, a 137.50% increase year-over-year.
- CASTLE BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $2.21M, a 9.37% increase from fiscal 2024.
- CASTLE BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $2.02M, a 649.81% increase from fiscal 2023.
- CASTLE BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $269.00K, a 67.71% decline from fiscal 2022.
- CASTLE BIOSCIENCES, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $833.00K, a 80.33% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $95.00K 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $322.00K 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $2.21M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $77.00K 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $19.00K 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $18.00K 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $2.02M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.57M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $8.00K 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $65.00K 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $269.00K 10-K · filed 2026-02-26 | |
| 2023-09-30 | $13.00K 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $89.00K 10-Q · filed 2024-11-04 | |
| 2023-03-31 | $95.00K 10-Q · filed 2024-11-04 | |
| 2022-12-31 | $833.00K 10-K · filed 2025-02-27 | |
| 2022-09-30 | $166.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $110.00K 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $399.00K 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $4.23M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $1.52M 10-Q · filed 2022-11-02 | $4.77M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $1.35M 10-Q · filed 2022-11-02 | $3.54M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-03-31 | $991.00K 10-Q · filed 2022-11-02 | $2.51M derived: sum of 4 quarters · filed 2022-11-02 |
| 2020-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.59M 10-K · filed 2022-02-28 |
| 2020-09-30 | $292.00K 10-Q · filed 2021-11-08 | $704.00K derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $330.00K 10-Q · filed 2021-11-08 | $1.16M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-03-31 | $71.00K 10-Q · filed 2021-11-08 | $1.25M derived: sum of 4 quarters · filed 2021-11-08 |
| 2019-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $1.18M 10-K · filed 2021-03-11 |
| 2019-09-30 | $747.00K 10-Q · filed 2020-11-09 | $1.16M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $416.00K 10-Q · filed 2020-08-10 | $453.94K derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $1.00K 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $304.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $38.00K 10-K · filed 2020-03-10 |
| 2018-09-30 | $36.63K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |